World's Best Scientists 2026 revealed!
Richard G. Wunderink

Richard G. Wunderink

D-Index & Metrics

Medicine

D-Index
100
Citations
54613
World Ranking
8132
National Ranking
4215

Richard G. Wunderink publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard G. Wunderink sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 479 publications — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Richard G. Wunderink D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard G. Wunderink sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 100 D-Index — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Richard G. Wunderink is affiliated with Northwestern University in the United States with a research focus primarily in the field of Medicine. Their work centers on key subfields including Epidemiology, Infectious Diseases, Critical Care and Intensive Care Medicine, Pulmonary and Respiratory Medicine, and Molecular Medicine.

The main topics addressed in their research reflect a concentration on respiratory and infectious conditions. These include Pneumonia and Respiratory Infections, Nosocomial Infections in ICU, Antibiotic Resistance in Bacteria, Respiratory Support and Mechanisms, COVID-19 Clinical Research Studies, Respiratory Viral Infections Research, and Antibiotics Pharmacokinetics and Efficacy.

Frequent co-authors who have collaborated with Richard G. Wunderink span several academics, highlighting ongoing research partnerships. These co-authors are:

  • Catherine A. Gao
  • Chiagozie I. Pickens
  • G. R. Scott Budinger
  • Benjamin D. Singer
  • Alexander V. Misharin

Richard G. Wunderink has multiple publications across notable journals and venues. The most common outlets for their work include:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • American Journal of Respiratory and Critical Care Medicine
  • Open Forum Infectious Diseases
  • CHEST Journal
  • Clinical Infectious Diseases

The following are selected significant recent publications authored or co-authored by Richard G. Wunderink, listed with their full titles, venues, and years of publication:

  • Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial, 2020, The Lancet Infectious Diseases
  • Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia, 2021, Nature
  • Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial, 2020, The Lancet Infectious Diseases
  • Pneumonia, 2021, Nature Reviews Disease Primers
  • Local and systemic responses to SARS-CoV-2 infection in children and adults, 2021, Nature

Best Publications

  • Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

    Lionel A. Mandell;Richard G. Wunderink;Antonio Anzueto;John G. Bartlett

  • Community-acquired pneumonia requiring hospitalization among U.S. adults

    Seema Jain;Derek J. Williams;Sandra R. Arnold;Krow Ampofo

  • International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia

    Antoni Torres;Michael S Niederman;Jean Chastre;Santiago Ewig

  • Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies: A consensus statement

    G. D. Campbell;M. S. Niederman;W. A. Broughton;D. E. Craven

  • Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial

    E Abraham;R Wunderink;H Silverman;T M Perl

  • MERS, SARS and other coronaviruses as causes of pneumonia

    Yudong Yin;Richard G. Wunderink

  • International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

    Brian T. Tsuji;Jason M. Pogue;Alexandre P. Zavascki;Mical Paul;Mical Paul

  • Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock

    Edward Abraham;Antonio Anzueto;Guillermo Gutierrez;Sidney Tessler

  • Linezolid vs Vancomycin: Analysis of Two Double-Blind Studies of Patients With Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia

    Richard G. Wunderink;Jordi Rello;Sue K. Cammarata;Rodney V. Croos-Dabrera

  • Noninvasive positive pressure ventilation via face mask : first-line intervention in patients with acute hypercapnic and hypoxemic respiratory failure

    G. Umberto Meduri;Robert E. Turner;Nabil Abou-Shala;Richard Wunderink

  • Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.

    Matteo Bassetti;Roger Echols;Yuko Matsunaga;Mari Ariyasu

  • Angiotensin II for the Treatment of Vasodilatory Shock.

    Ashish Khanna;Shane W. English;Xueyuan S. Wang;Kealy Ham

  • Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.

    Richard G. Wunderink;Michael S. Niederman;Marin H. Kollef;Andrew F. Shorr

  • Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

    Mitchell P. Fink;David R. Snydman;Michael S. Niederman;Kenneth V. Leeper Jr.

  • Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.

    Ethan Rubinstein;Sue K. Cammarata;Thomas H. Oliphant;Richard G. Wunderink

  • Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia

    Grant W. Waterer;Grant W. Somes;Richard G. Wunderink

  • Ventilator-associated pneumonia due to Pseudomonas aeruginosa.

    Susan Crouch Brewer;Richard G. Wunderink;Carol B. Jones;Kenneth V. Leeper

  • Validation of Cell-Cycle Arrest Biomarkers for Acute Kidney Injury Using Clinical Adjudication

    Azra Bihorac;Lakhmir S. Chawla;Andrew D. Shaw;Ali Al-Khafaji

  • Community Acquired Pneumonia

    Richard G Wunderink;Grant W Waterer

  • Analysis of Two Double-Blind Studies of Patients With Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia

    Richard G. Wunderink;Jordi Rello;Sue K. Cammarata;Rodney V. Croos-Dabrera

Frequent Co-Authors

Carlos G. Grijalva
Carlos G. Grijalva Vanderbilt University Medical Center
Evan J. Anderson
Evan J. Anderson Emory University
Kathryn M. Edwards
Kathryn M. Edwards Vanderbilt University Medical Center
Jonathan A. McCullers
Jonathan A. McCullers University of Tennessee Health Science Center
Marin H. Kollef
Marin H. Kollef Washington University in St. Louis
Michael S. Niederman
Michael S. Niederman Cornell University
Jordi Rello
Jordi Rello Instituto de Salud Carlos III
Antoni Torres
Antoni Torres University of Barcelona
Andrew T. Pavia
Andrew T. Pavia University of Utah
Antonio Anzueto
Antonio Anzueto The University of Texas Health Science Center at San Antonio

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens up more options than just traditional MD programs. Many students choose alternative online degree pathways for greater flexibility and faster career advancement. For those looking to become a registered nurse quickly, fast track medical LPN programs can provide a swift and practical entry into healthcare.

Aspiring nurses can also consider doctoral options, like DNP programs without dissertation, designed for working professionals who prefer a streamlined approach to advanced nursing practice. Mental health is another rapidly growing field. The psychiatric NP programs available online offer a flexible path for nurses aiming to specialize in psychiatric and mental health care.

For those interested in healthcare leadership, pursuing an online master of health administration can prepare you for administrative, management, or executive roles in hospitals and healthcare organizations. These non-traditional avenues can help you carve out a rewarding and impactful career in medicine.

Best Scientists Citing Richard G. Wunderink

Trending Scientists

Recently Published Articles